Longboard Pharmaceuticals (NASDAQ: LBPH)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-08 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.550 | -0.560 | -0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Longboard Pharmaceuticals (NASDAQ: LBPH) through any online brokerage.
Other companies in Longboard Pharmaceuticals’s space includes: Opiant Pharma (NASDAQ:OPNT), WAVE Life Sciences (NASDAQ:WVE), Satsuma Pharmaceuticals (NASDAQ:STSA), SCYNEXIS (NASDAQ:SCYX) and Lipocine (NASDAQ:LPCN).
The latest price target for Longboard Pharmaceuticals (NASDAQ: LBPH) was reported by HC Wainwright & Co. on Wednesday, April 27, 2022. The analyst firm set a price target for 25.00 expecting LBPH to rise to within 12 months (a possible 460.54% upside). 2 analyst firms have reported ratings in the last year.
The stock price for Longboard Pharmaceuticals (NASDAQ: LBPH) is $4.46 last updated May 23, 2022, 8:00 PM UTC.
There are no upcoming dividends for Longboard Pharmaceuticals.
Longboard Pharmaceuticals’s Q2 earnings are confirmed for Monday, August 8, 2022.
There is no upcoming split for Longboard Pharmaceuticals.
Longboard Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.